The Patent Finder
AO

Axelia Oncology Pty Ltd.

First filing 2013
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Ena Therapeutics Pty Ltd. (to 2022)

One patent currently held, every record listed here

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2039. from the record

Of the 5 now held by other companies, 4 name Ena Respiratory Pty Ltd. as their current owner, and 1 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2039
Next term end
1
Patent families

When these terms end

Each bar runs from grant to computed term end. 2017 to 2040.
US 9,889,195 Immunogenic Composition and Uses Thereof Apr 9, 2029
US 10,406,100 Novel Immunostimulatory Method Sep 22, 2031
US 11,786,458 Immunostimulatory Method Sep 22, 2031
US 9,676,819 Novel Immunostimulatory Method Oct 10, 2031
US 12,195,557 Optimised Compounds Sep 4, 2039
US 12,709,596 Novel Molecules Aug 17, 2040
20222027203220372040
3 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 13 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2031.
Ends Oct 2031 · High confidence
Also notable
Granted 2018 and renewed at every maintenance window due so far. Protection runs to 2029.
Ends Apr 2029 · Medium confidence
Also notable
Granted 2026. Too new for citation comparison; protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Ends Aug 2040 · Medium confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Optimised Compounds1 in forceto Sep 2039

Patents held now

Soonest term end first.

Showing 1 to 1 of 1

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 12,195,557Optimised Compounds
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 1: 5 patents in force now held by others · 3 applications pending. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited